VivoSim Labs, Inc. (VIVS) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.20
—
5yr avg: N/A
ROE
↑
-35.3%
↓+50% vs avg
5yr avg: -70.0%
30Y Low-155%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VIVS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
VivoSim Labs, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | — | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $-6692774 | — | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.83 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 25.54 | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.20 | — | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VIVS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
VIVS Profitability
Margins and return-on-capital ratios measuring operating efficiency
VivoSim Labs, Inc. earns an operating margin of -8761.1%. Operating margins have compressed from -4792.2% to -8761.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -35.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 96.5% | 100.0% | 100.0% | 100.0% | — | 85.1% | 84.4% | 77.6% | 77.4% | 100.0% |
| Operating Margin | -8761.1% | -8761.1% | -13840.4% | -4792.2% | -765.3% | — | -977.9% | -882.4% | -766.3% | -911.9% | -2605.7% |
| Net Profit Margin | -1727.8% | -1727.8% | -13459.6% | -4664.6% | -763.2% | — | -852.0% | -861.7% | -756.1% | -908.9% | -2601.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -35.3% | -35.3% | -155.0% | -75.8% | -33.0% | -51.1% | -59.5% | -65.9% | -65.1% | -61.7% | -69.6% |
| ROA | -23.7% | -23.7% | -110.1% | -64.4% | -31.3% | -49.2% | -54.2% | -58.9% | -58.5% | -56.2% | -63.7% |
| ROIC | -854.0% | -854.0% | -576.2% | -479.2% | -310.3% | -2279.9% | — | -6007.5% | -11232.8% | — | -32202.5% |
| ROCE | -163.8% | -163.8% | -142.8% | -73.0% | -32.3% | -51.1% | -67.6% | -66.5% | -65.1% | -61.1% | -69.1% |
VIVS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $11M exceeds total debt of $942000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.39 | 0.12 | 0.07 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -0.42 | -0.88 | -0.88 | -0.95 | -1.03 | -1.00 | -0.98 | -1.01 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1261.60 | -1261.60 | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($11M) exceeds total debt ($942000)
VIVS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
VivoSim Labs, Inc.'s current ratio of 3.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.64x to 3.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.25 | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 | 15.65 | 10.32 | 10.04 | 10.83 | 14.18 |
| Quick Ratio | 3.25 | 3.25 | 1.96 | 4.64 | 21.35 | 53.26 | 15.65 | 10.19 | 9.86 | 10.74 | 14.10 |
| Cash Ratio | 3.03 | 3.03 | 1.56 | 4.36 | 20.73 | 51.82 | 15.11 | 9.76 | 9.39 | 10.44 | 13.83 |
| Asset Turnover | — | 0.01 | 0.02 | 0.02 | 0.05 | — | 0.08 | 0.08 | 0.09 | 0.06 | 0.02 |
| Inventory Turnover | 0.98 | — | — | — | — | — | — | 0.98 | 1.22 | 1.74 | — |
| Days Sales Outstanding | — | 76.04 | 110.50 | 149.95 | — | — | 18.45 | 65.89 | 81.52 | 55.83 | 63.75 |
VIVS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
VivoSim Labs, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $1M | $762076 | $726085 | $725299 | $575166 | $539817 | $480749 | $446849 | $407345 | $375238 |
Peer Comparison
Compare VIVS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VIVSYou | $4M | -0.8 | — | — | 96.5% | -8761.1% | -35.3% | -854.0% | — |
 IMNM | $3B | -9.1 | — | — | — | -3228.8% | -52.1% | -1228.6% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RXRX | $1B | -2.3 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 SDGR | $992M | -9.4 | — | 79.7 | 55.7% | -65.2% | -26.3% | -39.4% | — |
 ABSI | $894M | -6.8 | — | — | -319.4% | -4454.2% | -62.5% | -58.0% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 SEER | $105M | -1.4 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See VIVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VIVS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VIVS vs IMNM
Side-by-side business, growth, and profitability comparison vs Immunome, Inc..
Start ComparisonVIVS — Frequently Asked Questions
Quick answers to the most common questions about buying VIVS stock.
What is VivoSim Labs, Inc.'s P/E ratio?
VivoSim Labs, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
What is VivoSim Labs, Inc.'s ROE?
VivoSim Labs, Inc.'s return on equity (ROE) is -35.3%. The historical average is -71.2%.
Is VIVS stock overvalued?
Based on historical data, VivoSim Labs, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are VivoSim Labs, Inc.'s profit margins?
VivoSim Labs, Inc. has 96.5% gross margin and -8761.1% operating margin.